philipp ivanyi (@IvanyiPhilipp) header
philipp ivanyi (@IvanyiPhilipp) profile picture

Adjunct Professor Hematology and Oncology, Clinical Trials, GU/Head and Neck/Sarcoma Center and Rare Cancers

Hannover Medical School
Joined January 2018
Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)Photo by philipp ivanyi (@IvanyiPhilipp)
DPD-Deficancy-The last Part of a year causes deficancy of Energy in a happy way by DPD: Discussions-Presentations-and dialogue with gerate collegues in mutinational conferences/Meetings/ Thx to all of U!#DGHO26#ESMO26#CareOnRareMiddleEast26#desmoid#kidneyCancer#SCCHN
33
We are part of the Uromigos world Cup and need your support to bring #theranostics to Nashville. Please share, like or comment to collect points and support our team
🇩🇪 Team Germany is bringing innovation to the Uromigos World Cup! ⚽🏆 Two cities, two research teams, and the latest advances in molecular imaging and theranostics for prostate and kidney cancer. Will their scientific expertise be enough to bring home the cup? 👀 #UromigosLive
1
8
12
912
philipp ivanyi retweeted
📣 New: ESMO Advanced and Metastatic Prostate Cancer Living Guideline, with recommendations and algorithms from the 2026 CPG, in a mobile friendly interactive format. Prepared by K Fizazi and S Gillessen 🔗 ow.ly/NYmf50Z9jO7 #ClinicalPracticeGuideline #ESMOGuidelines
1
2
4
921
philipp ivanyi retweeted
ASCO 2026 brought exciting data that will improve outcome for pts globally. Our MIBC organ preservation trial was presented by Nick.I presented cis v Carbo data from DISCUS trial. We saw amazing and exciting data across cancers.Thank you @asco committees for a stimulating meeting
3
10
394
philipp ivanyi retweeted
POTOMAC QOL: A year of durvalumab with BCG shows a delay in DFS and is FDA approved #ASCO26 . Here durvalumab appears to have little effect on QOL. We know ICIs have a ~10% rate of life changing toxicity (~10% @BethN01 ) which ⬇️QOL. New tools/methods are needed to unpick the details for patients.
1
37
1
53
4,949
philipp ivanyi retweeted
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM #ASCO26 | @ASCO
8
345
29
1,191
73,072
philipp ivanyi retweeted
Outcomes with enfortumab vedotin rechallenge after disease progression in metastatic #UrothelialCarcinoma. Presentation by @MichalSternsch @MSKCancerCenter. #ASCO26 written coverage by @RKSayyid @UAUrology > bit.ly/4viTUgb @ASCO
9
9
848
philipp ivanyi retweeted
CaboNivo final results in non-clear cell RCC presented by Dr Darren Feldman: ORR 43% in Cohort 1 (papillary, unclassified, tRCC), with a striking 88% ORR in FH-deficient RCC. mPFS 11 mo, mOS 28 mo. No responses in chromophobe RCC. CaboNivo confirmed as a standard 1L option for these rare subtypes. #ASCO26 #RCC @OncoAlert @ASCO @OncBrothers
2
37
73
4,313
Proud of @charlesbnguyen @cityofhope who just gave a phenomenal overview of #papillary #kidneycancer therapy at #ASCO26. He has been building an impressive portfolio of studies at @cityofhopeoc in GU cancers! Great perspectives shown today including data from @DrChoueiri, @tompowles1, @crisuarez08, @scocmem, @AlbigesL, @mzugman, @theNCI & from this very meeting from @DrDarrenFeldman for cabo/nivo.
1
23
2
54
2,796
philipp ivanyi retweeted
EXCEED #ASCO26: LY4101174 = More data on Nectin4/Topo1 ADCs in 86 patients with pretreated advanced UC . RRs 20% is lower than expected while haem tox was high. Efficacy and toxicity balance doesn’t support further development. Yesterdays data (LY405 same payload/target) has ⬆️ efficacy and is a preferential agent for R3 development IMO. Not all ADCs with matching target and payload are the same.@OncoAlert
1
13
1
27
5,530
philipp ivanyi retweeted
Clear cell RCC sheds low levels of ctDNA, but positivity and ctDNA dynamics are relevant in the adjuvant setting @DrChoueiri #ASCO26. This analysis is with an exome based personalised technique and shows a lack of sensitivity (5-8% ctDNA+ve rate vs 40% radiological relapse rate) but good specificity (almost all ctDNA +ves relapse). Whole genome ctDNA analysis should work work better. There is a future for ctDNA in renal cancer, we’re just not quite there yet IMO.
5
42
2
91
8,498
philipp ivanyi retweeted
THE @ONCOALERT RoundUp🚨 DAY 3 of #ASCO26 🚨For the FULL NEWSLETTER 👉buff.ly/25YHTzM 🔹 #RASolute302: Daraxonrasib became the first RAS-targeted therapy to improve OS in previously treated metastatic pancreatic cancer (13.2 vs 6.6 mo). 🔹 #LIBRETTO: Adjuvant selpercatinib cut recurrence/progression risk by 83% in RET+ early-stage NSCLC. 🔹 #PROTEUS: Perioperative apalutamide improved pathologic response and long-term outcomes in high-risk localized prostate cancer. 🔹 #BREAKWATER: EC + FOLFIRI further expanded frontline options for BRAF V600E mCRC. 🔹 #HorizonCRC01: Trastuzumab rezetecan showed strong activity in refractory HER2+ mCRC. 🔹 #PLUDO: New data inform optimal sequencing of LuPSMA and docetaxel in mCRPC. 🔹 #OBX115: IL-15–engineered TIL therapy achieved a 67% ORR in heavily pretreated melanoma. 🔹 Ultra-low-dose nivolumab + metronomic chemotherapy improved survival and QoL in recurrent/metastatic HNSCC. 🔹 #SARC041: Abemaciclib became the first CDK4 inhibitor to improve PFS in dedifferentiated liposarcoma. @GIMedOnc @DrChoueiri @jamecancerdoc @Rodrosb @YannickBuccella @HHorinouchi @MarioBalsaMD @g_mountzios @OncBrothers @lungoncdoc @diegoadiazg @AnaVManana @UOzkerim @declangmurphy @DrYukselUrun @DrSpratticus @tugbawitter @DrRishabhOnco @KalantriShreyas @josemarciofigu1 @nataliagandur @DraMartinezLago @ozdogan_md
1
17
10
31
10,154
philipp ivanyi retweeted
Dear Colleagues at #ASCO26 A Great pleasure to bring you from the podium to your feed our amazing GU Faculty Dr. Tom Powles 🇬🇧presenting EV302 With 3.5 years of follow-up, EV plus pembrolizumab continues to demonstrate durable survival benefits over platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. Median overall survival reached 33.6 months versus 15.9 months with chemotherapy, without new safety signals. Notably, two-thirds of patients achieving complete response initially had partial responses, often converting after additional treatment cycles, highlighting the importance of treatment duration in maximizing long-term outcomes. asco.org/abstracts-presentat… @tompowles1 @MichvdHeijden @MattGalsky @y_loriot @IyerGopa @JCensits @mar_nataliya @CVulsteke @KalaSridh @shilpaonc @OncoAlert @nataliagandur @scocmem @AmandaNizamMD @WeOncologists @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini @weoncologists
1
16
5
33
7,149
philipp ivanyi retweeted
The 3.5yr OS from EV302 continues to show transformative benefit (HR 0.53 (0.45-0.63)) #ASCO26 for EV/pembro. The landmark OS for the CR population (30%) is ~90%. Median time to CR is 4.5 months (responses mature over time). Response rates of platinum chemo after EVP is 21% (OS 11 months). This should be considered a 2nd line standard. Median duration of EV was 7 months - longer in responders. Optimal duration of EV trials are needed. @OncoAlert
4
67
6
129
9,332
philipp ivanyi retweeted
ASCO 2026 | Tag 1 Niere Prof. Dr. Peter J. Goebell und PD Dr. Philipp Ivanyi diskutieren die wichtigsten Daten des ersten Kongresstages zum Nierenzellkarzinom – von aktuellen Adjuvanz-Daten bis zur Frage, wie wir Therapieerfolg aus Patientensicht bewerten. ▶️ Jetzt ansehen. #ASCO26 #Nierenzellkarzinom #Uroonkologie #onkowissenTV
2
1
157
#REVIEW 🚨 How does #exercise reduce cancer risk? Zhuang et al. propose that physiological adaptation to aerobic activity reshapes adult stem cell behaviour, limiting transformation and tumour initiation 📖⬇️ dlvr.it/TSfZHT
2
41
1
102
6,943
philipp ivanyi retweeted
Duration of response to UGN-102 by age at baseline across 3 clinical trials in patients with recurrent low-grade intermediate risk #BladderCancer. Presentation by @UroDocAsh @UTMDAnderson. #AUA26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4u6FVtI @AmerUrological
8
5
705